bluebird bio, Inc. – NASDAQ:BLUE

Add to watchlist

$4.99

-3.78

-43.17%

Market closed

Open in about 7 hours

+619.67%

month

+619.67%

quarter

+527.14%

year

Market Cap	76.22M
Enterprise value	168.61M

P/E	-0.94
EV/Sales	47.65
EV/EBITDA	-0.57
Price/Sales	0.06
Price/Book	N/A
PEG ratio	-0.01
EPS	-0.62

Revenue	21.72M
EBITDA	-228.11M
Income	-78.36M
Revenue Q/Q	17353.52%
Revenue Y/Y	322.58%

Profit margin	-8449.85%
Oper. margin	-8837.84%
Gross margin	-184.44%
EBIT margin	-8837.84%
EBITDA margin	-1050.01%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

bluebird bio, Inc. (NASDAQ:BLUE): Profit margin
Dec 2022	62K	32.23M	51987.1%
Mar 2023	2.38M	34.04M	1429.78%
Jun 2023	6.89M	-72.90M	-1058.17%
Sep 2023	12.39M	-71.73M	-578.85%

bluebird bio Financials Estimate

Q Y

bluebird bio, Inc. (NASDAQ:BLUE): Analyst Estimates
Sep 2025	84.91M	-16.63M	-19.59%
Dec 2025	99.26M	-9.81M	-9.89%
Mar 2026	93.42M	-23.48M	-25.14%
Jun 2026	108.90M	-18.08M	-16.6%

Analysts Price target
Financials & Ratios estimates

bluebird bio, Inc. (NASDAQ:BLUE): Debt to assets
Dec 2022	554902000	358.55M	64.62%
Mar 2023	692736000	337.99M	48.79%
Jun 2023	663393000	374.37M	56.43%
Sep 2023	613608000	391.07M	63.73%

bluebird bio, Inc. (NASDAQ:BLUE): Cash Flow
Dec 2022	-56.27M	103.24M	-115K
Mar 2023	-86.63M	82.13M	130.45M
Jun 2023	-72.72M	6.94M	-445K
Sep 2023	-61.84M	62.08M	-42K

bluebird bio alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

bluebird bio, Inc. (NASDAQ:BLUE): Employee count
Aug 2023	323
Sep 2023	323
Oct 2023	323
Nov 2023	323
Dec 2023	323
Jan 2024	323
Feb 2024	323
Mar 2024	323
Apr 2024	323
May 2024	323
Jun 2024	323
Jul 2024	323

bluebird bio
Hedge Funds Holdings Q1 2022

58.17% +3.34%

of BLUE is owned by hedge funds

158 +3

hedge funds hold BLUE stock

61.62M +3.53M

shares is hold by hedge funds

BLUE hedge funds holdings changes

bluebird bio, Inc. (NASDAQ:BLUE): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	3759
Feb 2024	0	9810
Mar 2024	0	17438
Jun 2024	0	3834
Sep 2024	0	35786
Dec 2024	0	3795

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	10 Dec 2024	OBENSHAIN ANDREW director, officer: President and CEO director, officer: President an..	Common Stock	971	$0.42	$405
Sale	10 Dec 2024	COLVIN RICHARD A officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	2,824	$0.42	$1,178
Sale	30 Sep 2024	KLIMA THOMAS J officer: See Remarks officer: See Remarks	Common Stock	1,006	$0.53	$529
Sale	30 Sep 2024	OBENSHAIN ANDREW director, officer: President and CEO director, officer: President an..	Common Stock	34,780	$0.53	$18,260
Sale	3 Jun 2024	KLIMA THOMAS J officer: See Remarks officer: See Remarks	Common Stock	3,834	$0.97	$3,727
Sale	4 Mar 2024	OBENSHAIN ANDREW director, officer: President and CEO director, officer: President an..	Common Stock	6,095	$1.53	$9,313
Sale	4 Mar 2024	KLIMA THOMAS J officer: See Remarks officer: See Remarks	Common Stock	4,573	$1.53	$6,988
Sale	1 Mar 2024	COLVIN RICHARD A officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	6,770	$1.53	$10,345
Sale	5 Feb 2024	KLIMA THOMAS J officer: See Remarks officer: See Remarks	Common Stock	2,714	$0.9	$2,451
Sale	5 Feb 2024	VITTIGLIO JOSEPH officer: Chief Business & Legal Officer officer: Chief Business & Legal..	Common Stock	5,217	$0.9	$4,711

Status	Patent	Filling date	Issue date
Application	Application VECTORS AND COMPOSITIONS FOR TREATING HEMOGLOBINOPATHIES Filling date: 28 Jan 2022 Issue date: 18 Aug 2022	28 Jan 2022	18 Aug 2022
Application	Application BETA-THALASSEMIA POTENCY ASSAY Filling date: 27 Mar 2020 Issue date: 26 May 2022	27 Mar 2020	26 May 2022
Application	Application SICKLE CELL POTENCY ASSAY Filling date: 20 Mar 2020 Issue date: 19 May 2022	20 Mar 2020	19 May 2022
Application	Application METHODS AND SYSTEMS FOR MANUFACTURING VIRAL VECTORS Filling date: 22 Jan 2020 Issue date: 7 Apr 2022	22 Jan 2020	7 Apr 2022
Application	Application DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES Filling date: 13 Dec 2019 Issue date: 27 Jan 2022	13 Dec 2019	27 Jan 2022
Application	Application CD79A CHIMERIC ANTIGEN RECEPTORS Filling date: 14 Jun 2019 Issue date: 26 Aug 2021	14 Jun 2019	26 Aug 2021
Application	Application NKG2D DARIC RECEPTORS Filling date: 14 Dec 2018 Issue date: 5 Aug 2021	14 Dec 2018	5 Aug 2021

bluebird bio
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 11 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 26 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 7 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 8 Aug 2023	Q2 2023 Earnings Call Transcript

BLUE earnings call transcripts

bluebird bio
Executives

Insider	Age	Since	Compensation
Mr. Nick Leschly (1973) Pres & Director	52		$841,950
Mr. William D. Baird III (1972) Principal Financial & Accounting Officer	53		$718,610

bluebird bio
Latest News

Sunday, 8 December 2024
12:30	bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition	businesswire.com
Saturday, 7 December 2024
12:00	Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels	businesswire.com
Friday, 6 December 2024
14:58	ISS Recommends Dye & Durham Shareholders Vote the BLUE Proxy Card “FOR” Three of Engine Capital's Directors, Including Proposed Chair and Interim CEO Hans Gieskes	businesswire.com
Wednesday, 4 December 2024
16:05	bluebird bio Announces 1-for-20 Reverse Stock Split	businesswire.com
08:47	bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model	businesswire.com
Monday, 2 December 2024
09:00	THE DISTINCT COBALT BLUE OF SARATOGA® SPRING WATER NOW HAS AN OFFICIAL PANTONE® COLOR: SARATOGA® SIGNATURE BLUE, COLOR 286 C	prnewswire.com
Wednesday, 27 November 2024
11:45	FDA investigates risk of blood cancers from bluebird bio's gene therapy	reuters.com
Monday, 25 November 2024
09:00	WYNNEFIELD GROUP SENDS DEFINITIVE PROXY MATERIALS TO TECHPRECISION STOCKHOLDERS, INCLUDING A BLUE PROXY CARD AND A LETTER SEEKING TO HOLD MEMBERS OF THE BOARD ACCOUNTABLE FOR YEARS OF POOR OPERATING RESULTS, POOR PERFORMANCE AND A SERIES OF COSTLY STRATEGIC MISSTEPS	prnewswire.com
Wednesday, 20 November 2024
16:53	BLUE OWL CAPITAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Blue Owl Capital Corporation III - OBDE	businesswire.com
08:10	My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys	seekingalpha.com
Friday, 15 November 2024
14:05	JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options	benzinga.com
12:38	bluebird bio downgraded by Bank of America, shares tumble	proactiveinvestors.com
Thursday, 14 November 2024
10:06	bluebird bio, Inc. (BLUE) Q3 2024 Earnings Call Transcript	seekingalpha.com
09:10	Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates	zacks.com
Friday, 8 November 2024
10:36	After Plunging -22.76% in 4 Weeks, Here's Why the Trend Might Reverse for Bluebird (BLUE)	zacks.com
Tuesday, 5 November 2024
09:05	bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition	businesswire.com
Tuesday, 8 October 2024
15:53	Bluebird Bio (BLUE) Stock Dips Amid Market Volatility	gurufocus.com
Friday, 4 October 2024
16:05	bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Wednesday, 2 October 2024
16:11	Bluebird Bio (BLUE) Stock Surges 5.04% Amid Market Movements	gurufocus.com
Friday, 27 September 2024
16:30	bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing	businesswire.com
Tuesday, 24 September 2024
07:08	Bluebird bio to cut 25% of workforce as part of restructuring	reuters.com
07:00	bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025	businesswire.com
Monday, 16 September 2024
17:02	2 Penny Stocks To Buy With Just $250	247wallst.com
Friday, 12 July 2024
21:00	BLUE ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm	globenewswire.com
Wednesday, 3 July 2024
07:00	Blue Thunder Name Change and Muus Project Update	newsfilecorp.com
Thursday, 27 June 2024
21:00	BLUE ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm	globenewswire.com
Tuesday, 25 June 2024
07:00	Blue Thunder Mining Inc. Appoints Alain Levesque CFO; Announces Board Change	newsfilecorp.com
Monday, 17 June 2024
15:27	7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline	investorplace.com
Tuesday, 4 June 2024
09:15	Independent Proxy Advisor Glass Lewis Recommends Medallion Shareholders Vote “FOR” Both of the Board's Director Nominees on the BLUE Proxy Card	globenewswire.com
07:00	Blue Thunder Mining Inc. Changing Name to Orbec Gold Mines Inc., Moving Headquarters to Brossard, Quebec	newsfilecorp.com

Ideas & Opinions

Seeking Alpha 9 Jul 2024

Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management
Seeking Alpha 24 Apr 2024

Crispr Therapeutics: Now Is The Time To Buy
Seeking Alpha 24 Apr 2024

Hercules Capital: Winning Option In The Financial Services Space
Seeking Alpha 25 Jan 2024

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024
Seeking Alpha 5 Jan 2024

Agios Pharmaceuticals: Strong Thalassemia Data Makes A Tempting Bull Case
Seeking Alpha 4 Jan 2024

CRISPR Therapeutics: Therapies Of The Future Are Almost Here, But Not Yet
Seeking Alpha 9 Dec 2023

Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed
Seeking Alpha 29 Nov 2023

Buy bluebird bio's Lovo-Cel As It Transforms Sickle Cell Disease Treatment
Seeking Alpha 10 Nov 2023

Beam Therapeutics: Sale Of Rights To Verve's In Vivo Candidates An Odd Decision
Seeking Alpha 11 Oct 2023

Editas Medicine: A Mispriced Contender In The Gene Editing Arena

Frequently Asked Questions (FAQ)

What's the price of bluebird bio stock today?

One share of bluebird bio stock can currently be purchased for approximately $4.99.
When is bluebird bio's next earnings date?

Unfortunately, bluebird bio's (BLUE) next earnings date is currently unknown.
Does bluebird bio pay dividends?

No, bluebird bio does not pay dividends.
How much money does bluebird bio make?

bluebird bio has a market capitalization of 76.22M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 720.04% to 29.5M US dollars.
What is bluebird bio's stock symbol?

bluebird bio, Inc. is traded on the NASDAQ under the ticker symbol "BLUE".
What is bluebird bio's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of bluebird bio?

Shares of bluebird bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are bluebird bio's key executives?
bluebird bio's management team includes the following people:
- Mr. Nick Leschly Pres & Director(age: 52, pay: $841,950)
- Mr. William D. Baird III Principal Financial & Accounting Officer(age: 53, pay: $718,610)
How many employees does bluebird bio have?

As Jul 2024, bluebird bio employs 323 workers.
When bluebird bio went public?

bluebird bio, Inc. is publicly traded company for more then 12 years since IPO on 19 Jun 2013.
What is bluebird bio's official website?

The official website for bluebird bio is bluebirdbio.com.
Where are bluebird bio's headquarters?

bluebird bio is headquartered at 60 Binney Street, Cambridge, MA.
How can i contact bluebird bio?

bluebird bio's mailing address is 60 Binney Street, Cambridge, MA and company can be reached via phone at +33 94999300.

bluebird bio, Inc.

bluebirdbio.com

Exchange:

NASDAQ

Full time employees:

375

Industry:

Biotechnology

Sector:

Healthcare

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

+33 94999300

60 Binney Street
Cambridge, MA 02142

CIK: 0001293971
ISIN: US09609G1004
CUSIP: 09609G100